Low-dose tamoxifen, known as “baby TAM,” is emerging as an alternative breast cancer prevention treatment. It intends to reduce side effects while maintaining efficacy in high-risk individuals. Studies presented at the San Antonio Breast Cancer Symposium (SABCS) looked at baby TAM users’ risk understanding and medication adherence. Another study examined the efficacy of different tamoxifen doses, using breast density changes as a proxy for outcomes. The study showed that lower doses of tamoxifen were as effective as the standard 20-mg dose. These results are promising for the use of low-dose tamoxifen as an option for preventing breast cancer in high-risk individuals. More research is still needed in this area.
Source link